Vidal-Jove Joan, Perich Eloi, Del Castillo Manuel Alvarez
Surgical Oncology HIFU Unit, Hospital Universitari Mutua Terrassa (HUMT), Pl. Dr. Robert, 5, 08221 Terrassa, Barcelona, Spain. Electronic address: http://www.mutuaterrassa.cat.
Surgical Oncology HIFU Unit, Hospital Universitari Mutua Terrassa (HUMT), Pl. Dr. Robert, 5, 08221 Terrassa, Barcelona, Spain.
Ultrason Sonochem. 2015 Nov;27:703-706. doi: 10.1016/j.ultsonch.2015.05.026. Epub 2015 May 27.
We described the experience of the HIFU Onco Unit of Hospital University Mutua Terrassa (Barcelona, Spain) treating malignant tumors, focusing on results of unresectable pancreatic tumors treated with Ultrasound Guided High Intensity Focused Ultrasound (USgHIFU) hyperthermia ablation in combination with adjuvant chemotherapy.
From February 2008 to December 2013, we treated 140 malignant cases. Of those, 48 cases of unresectable pancreatic tumors were treated from March 2010 to December 2013, and the first 43 were included in the analysis. All the 43 cases (29 cases of stage III and 14 cases of stage IV) were treated with systemic chemotherapy. Clinical responses (thermical ablation achieved) were measured by image techniques, and complications were also recorded and analyzed.
The majority of the 140 cases treated at our HIFU center were pancreatic and liver tumors, among which 43 cases of pancreatic tumors were analyzed. Clinical responses (ablation obtained) were observed in 82% of the cases, and the responses lasted at 8 weeks post-procedure. We obtained 11 complete responses (25%) at the end of the combined treatment, nine from stage III patients and two from stage IV patients. Major complications included severe pancreatitis with GI bleeding (1), and skin burning of grade III that required plastic surgery (2). The median survival was 13 months (6 months-2.7 years). No deaths were registered during the course of the treatment.
HIFU is a potentially effective and safe modality for the treatment of malignant tumors. HIFU proves to have a survival advantage in treating unresectable pancreatic cancer.
我们描述了西班牙巴塞罗那Mutua Terrassa大学医院高强度聚焦超声（HIFU）肿瘤治疗单元治疗恶性肿瘤的经验，重点是超声引导下高强度聚焦超声（USgHIFU）热消融联合辅助化疗治疗不可切除胰腺肿瘤的结果。
2008年2月至2013年12月，我们共治疗了140例恶性病例。其中，2010年3月至2013年12月治疗了48例不可切除胰腺肿瘤，分析纳入了前43例。所有43例患者（29例III期和14例IV期）均接受了全身化疗。通过影像技术测量临床反应（热消融实现情况），并记录和分析并发症。
我们HIFU中心治疗的140例病例中，大多数为胰腺和肝脏肿瘤，其中分析了43例胰腺肿瘤病例。82%的病例观察到临床反应（获得消融），且反应在术后8周持续存在。联合治疗结束时获得11例完全缓解（25%），其中9例来自III期患者，2例来自IV期患者。主要并发症包括伴有胃肠道出血的严重胰腺炎（1例）和需要整形手术的III级皮肤灼伤（2例）。中位生存期为13个月（6个月至2.7年）。治疗过程中无死亡记录。
HIFU是一种治疗恶性肿瘤的潜在有效且安全的方式。HIFU在治疗不可切除胰腺癌方面显示出生存优势。
